BioCentury
ARTICLE | Clinical News

Subcutaneous C1-INH: Phase III started

February 24, 2014 8:00 AM UTC

CSL began the double-blind, crossover, U.S. Phase III COMPACT trial to evaluate subcutaneous C1-INH twice weekly in about 80 patients with HAE types I or II who have frequent attacks. Patients will re...